GlassScriptPhysician profile
Muhammad Q Cheema
NPI 1497966329
$5,045.65
in general payments reported to CMS, 2019-2025
23 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,230 · 2020: $92.73 · 2021: $281 · 2022: $301 · 2023: $806 · 2024: $782 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Education: $42.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.71 |
| Education | $42.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $2,196.48 | 2019 | |
| Mallinckrodt Hospital Products INC. | $289.90 | 2023-2024 | Acthar |
| Calliditas Therapeutics US INC. | $269.82 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $267.92 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $257.94 | 2021-2024 | |
| Vifor Pharma, INC. | $226.99 | 2021-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $225.39 | 2023-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $200.52 | 2023-2024 | |
| Daiichi Sankyo INC. | $157.25 | 2020-2023 | Injectafer |
| Akebia Therapeutics INC | $141.34 | 2024 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $118.04 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.66 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $99.67 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $92.90 | 2021-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $91.99 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $52.58 | 2024 | |
| Ardelyx, INC. | $51.84 | 2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $49.35 | 2022-2023 | Lupkynis |
| Lexicon Pharmaceuticals, INC. | $44.01 | 2023-2024 | Inpefa |
| Ultragenyx Pharmaceutical INC. | $32.39 | 2020 | |
| Bard Peripheral Vascular, INC. | $28.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $21.02 | 2021 | |
| Janssen Scientific Affairs, LLC | $15.14 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.